Maxim Group Sticks to Its Buy Rating for Agile Therapeutics (AGRX)

By Austin Angelo

Maxim Group analyst Caroline Palomeque maintained a Buy rating on Agile Therapeutics (AGRXResearch Report) today and set a price target of $3. The company’s shares opened today at $1.

Palomeque commented:

“Agile Therapeutics announced topline results from its comparative adhesion wear study of Twirla vs. Xulane (generic Otho-Evra). Twirla met its primary endpoint of non-inferiority to Xulane, which the FDA considers to have acceptable adhesion for a patch contraceptive. These results will be used to answer FDA adhesion questions from the 2017 CRL and will be included in the NDA package.”

According to TipRanks.com, Palomeque has 0 stars on 0-5 star ranking scale with an average return of -14.6% and a 31.6% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.

Agile Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.92 and a one-year low of $0.23. Currently, Agile Therapeutics has an average volume of 317K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch for use in contraception. It offers its product candidate Twirla, which is an investigational non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.